ArticlePloS one2011
The sodium iodide symporter (NIS) and potential regulators in normal, benign and malignant human breast tissue.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04492657 (Study on the Compensatory Mechanism of Iodine Nutrition and the Optimal Intake Level of Lactating Women), which is not on this map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Study on the Compensatory Mechanism of Iodine Nutrition and the Optimal Intake Level of Lactating Women
Who cites it
22 citing papers in PubMed, 36 citations in OpenAlex.
- NIS-Centered Reporter Gene Imaging and Radionuclide-Integrated Nanoplatforms for Quantitative Tracking of Immune Cell Therapy in Oncology and Inflammatory Disease Models.Pharmaceuticals (Basel, Switzerland) · 2026Review
- The extra-thyroidal distribution of sodium iodide symporter.Frontiers in endocrinology · 2025Review
- False-positive radioiodine uptake after radioiodine treatment in differentiated thyroid cancer.Endocrine · 2023Review
- Links between Breast and Thyroid Cancer: Hormones, Genetic Susceptibility and Medical Interventions.Cancers · 2022Review
- Hormonal Crosstalk Between Thyroid and Breast Cancer.Endocrinology · 2022Review
- Expression of pendrin and NIS iodide transporters in human breast tumor and peri-tumoral tissue.Archives of medical science : AMS · 2022Article
- Na+/I- symporter expression, function, and regulation in non-thyroidal tissues and impact on thyroid cancer therapy.Endocrine-related cancer · 2021Article
- The Comparison ofOpen access Macedonian journal of medical sciences · 2019Article
- The correlation between breast cancer and urinary iodine excretion levels.The Journal of international medical research · 2018Article
- ATRA increases iodine uptake and inhibits the proliferation and invasiveness of human anaplastic thyroid carcinoma SW1736 cells: Involvement of β-catenin phosphorylation inhibition.Oncology letters · 2017Article
- Investigating the association of rs2910164 with cancer predisposition in an Irish cohort.Endocrine connections · 2017Article
- All-trans retinoic acid suppresses malignant characteristics of CD133-positive thyroid cancer stem cells and induces apoptosis.PloS one · 2017Article
- MicroRNA-10a is reduced in breast cancer and regulated in part through retinoic acid.BMC cancer · 2015Article
- Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells.Breast cancer (Dove Medical Press) · 2015Article
- Sodium iodide symporter (NIS) in extrathyroidal malignancies: focus on breast and urological cancer.BMC cancer · 2014Review
- Objective assessment of image quality VI: imaging in radiation therapy.Physics in medicine and biology · 2013Article
- The sodium/iodide symporter NIS is a transcriptional target of the p53-family members in liver cancer cells.Cell death & disease · 2013Article
- Research resource: nuclear receptors as transcriptome: discriminant and prognostic value in breast cancer.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe presence, relevance and regulation of the Sodium Iodide Symporter (NIS) in human mammary tissue remains poorly understood. This study aimed to quantify relative expression of NIS and putative regulators in human breast tissue, with relationships observed further investigated in vitro.
methodsHuman breast tissue specimens (malignant n = 75, normal n = 15, fibroadenoma n = 10) were analysed by RQ-PCR targeting NIS, receptors for retinoic acid (RARα, RARβ), oestrogen (ERα), thyroid hormones (THRα, THRβ), and also phosphoinositide-3-kinase (PI3K). Breast cancer cells were treated with Retinoic acid (ATRA), Estradiol and Thyroxine individually and in combination followed by analysis of changes in NIS expression.
resultsThe lowest levels of NIS were detected in normal tissue (Mean(SEM) 0.70(0.12) Log(10) Relative Quantity (RQ)) with significantly higher levels observed in fibroadenoma (1.69(0.21) Log(10)RQ, p<0.005) and malignant breast tissue (1.18(0.07) Log(10)RQ, p<0.05). Significant positive correlations were observed between human NIS and ERα (r = 0.22, p<0.05) and RARα (r = 0.29, p<0.005), with the strongest relationship observed between NIS and RARβ (r = 0.38, p<0.0001). An inverse relationship between NIS and PI3K expression was also observed (r = 0.21, p<0.05). In vitro, ATRA, Estradiol and Thyroxine individually stimulated significant increases in NIS expression (range 6-16 fold), while ATRA and Thyroxine combined caused the greatest increase (range 16-26 fold).
conclusionAlthough NIS expression is significantly higher in malignant compared to normal breast tissue, the highest level was detected in fibroadenoma. The data presented supports a role for retinoic acid and estradiol in mammary NIS regulation in vivo, and also highlights potential thyroidal regulation of mammary NIS mediated by thyroid hormones.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.